^
Association details:
| Biomarker: | TGFBR2 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Identification of TGFBR2 mutation as a negative predictor of immunotherapy in NSCLC.
Published date:
05/19/2021
Excerpt:
...we demonstrated a 39-year-old case with TGFBR2 mutation who was treated with 3 mg/kg nivolumab as second-line treatment. The patient progressed after three cycles of nivolumab and the PFS was only 1.3 months.
DOI:
10.1200/JCO.2021.39.15_suppl.e21002
